Skip to Main Content
Our Commitment to Diversity
Peter Giunta

Pete Giunta advises clients on intellectual property issues and litigates patent and technology disputes. His experience spans a wide array of technologies, including pharmaceuticals, biopharmaceuticals, biotechnology, medical devices, diagnostics, and electronics. Before studying law, Pete worked in several pharmaceutical and chemical companies, which helps him understand the issues companies face, and practice with a business-minded approach.

Pharmaceuticals and biologics are a major part of Pete's practice. He helps clients navigate the interface between patent and food and drug law. Generic, brand, biosimilar, and over-the-counter drug companies rely on his input in developing strategies for FDA filings, product launches, and post-marketing protection. His experience spans many therapeutic areas, including cancer, diabetes, HIV/AIDS, central nervous system, asthma, and microbial diseases. It also spans many dosage forms, including solid oral formulations, sterile injectables, inhaled dosage forms, topical agents, and ophthalmic solutions.

Pete has litigated numerous Hatch-Waxman cases through trial and appeal. He has had cases in federal district courts, the U.S. Court of Appeals for the Federal Circuit, and the International Trade Commission (ITC). Pete is registered to practice before the U.S. Patent & Trademark Office and counsels clients on Patent Trial and Appeal Board proceedings such as inter partes reviews (IPRs). In addition to litigation, Pete has represented clients in negotiations, mediations, and AAA and LCIA arbitrations in patent, trademark, and commercial disputes.

He likewise provides patent infringement, validity, and freedom-to-operate opinions, and advises on prosecution and licensing.

  • Clerkship, Honorable Lawrence M. McKenna, U.S. District Court Judge in the Southern District of New York, 2004-2005
  • Practiced at a well-regarded New York intellectual property law firm, 2005-2014
  • Hon. William C. Conner Inn of Court
Additional Thought Leadership Pages
  • Mentioned, "Gilead, Cipla Ink Deal To End HIV Drug Buyers' Antitrust Suit," Law360, 1 March 2024
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel